ICON Plc - Company Profile
Powered by 
All the data and insights you need on ICON Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date ICON Plc Strategy Report
- Understand ICON Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
ICON Plc Catalyst Calendar
Proactively evaluate ICON Plc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of ICON Plc Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 29 Aug 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 28 Aug 2019 | Phase II Trial Completion | Biogen Inc; IQVIA Holdings Inc; PMG Research Inc | BIIB; IQV | litifilimab | Immunology | Acute Cutaneous Lupus Erythematosus (ACLE); Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE); Cutaneous Lupus Erythematosus; Subacute Cutaneous Lupus Erythematosus (SCLE); Systemic Lupus Erythematosus | Clinical Trial Registry |
| 23 Aug 2019 | Phase I Trial Completion | Bristol-Myers Squibb Co; PRA Health Sciences Inc | BMY | pegbelfermin | Gastrointestinal | Non Alcoholic Fatty Liver Disease (NAFLD); Non-Alcoholic Steatohepatitis (NASH) | Clinical Trial Registry |
| 20 Aug 2019 | Phase I Trial Completion | Johnson & Johnson; PRA Health Sciences Inc | JNJ | seltorexant | Central Nervous System | Insomnia; Major Depressive Disorder | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer